Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of KUX-1151 in Hyperuricemia and Gout
NCT02190786Phase 2Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of KUX-1151 in hyperuricemia and gout (3 arms), sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoints: Proportion of subjects achieving serum uric acid level <= 6 mg/dL at 14 weeks, Percent change from baseline in serum uric acid level at 14 weeks and 1 more. Status: completed.
02
Drugs
KUX-1151
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on NCT02190786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02190786.